AZTA vs BLFS
AZTA: Azenta is a provider of life sciences solutions focused on automated sample management and genomic services for research and clinical development. BLFS: BioLife Solutions develops biopreservation media and cell processing products designed to improve quality and reduce risk in cell and gene therapy manufacturing and distribution.
Side-by-side fundamentals
| Metric | AZTA | BLFS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.16 | $31.15 | |
| Market cap as of 2026-07-23 | $1.2B | $1.4B | |
| PEG as of 2026-07-23 | -0.04 | -0.20 | BLFS lower |
| Net margin as of 2026-07-23 | -29.9% | -3.0% | BLFS higher |
| Gross margin as of 2026-07-23 | +43.9% | +64.0% | BLFS higher |
| Operating margin as of 2026-07-23 | -28.9% | -15.4% | BLFS higher |
| ROE as of 2026-07-23 | -10.7% | -0.8% | BLFS higher |
| ROA as of 2026-07-23 | -8.8% | -0.8% | BLFS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | AZTA lower |
| Revenue growth (YoY) as of 2026-07-23 | -5.9% | +25.6% | BLFS higher |
| Revenue CAGR (3y) SEC XBRL | +2.2% | +30.9% | BLFS higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 1.39 | 1.92 | |
| 1-year return as of 2026-07-22 close | -15.1% | +40.6% | BLFS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.